Cargando…

YINGLONG: A Multicenter, Prospective, Non-Interventional Study Evaluating the Safety and Tolerability of Ticagrelor in Chinese Patients with Acute Coronary Syndrome

INTRODUCTION: Ticagrelor is an oral, reversible, direct-acting P2Y(12) receptor inhibitor approved for the prevention of cardiovascular events in acute coronary syndrome (ACS). In China, drug intensive monitoring regulations for new drugs require additional safety data post-approval. METHODS: YINGLO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Xin, Zheng, Yang, Yang, Ping, Ma, Shuren, Yu, Zaixin, Su, Xi, Ge, Junbo, Leonsson-Zachrisson, Maria, Wang, Xianhong, Sun, Jing, Bai, Lu, Ma, Chang-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822841/ https://www.ncbi.nlm.nih.gov/pubmed/31119693 http://dx.doi.org/10.1007/s12325-019-00972-z

Ejemplares similares

Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study
por: Gao, Runlin, et al.
Publicado: (2018)

A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
por: Johansson, Susanne, et al.
Publicado: (2016)

Ticagrelor does not impact patient‐reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study
por: Kanter, Julie, et al.
Publicado: (2018)

Effect of Ma Yinglong Shexiang hemorrhoids cream combined with pearl powder on the pain and complications of severe pressure ulcer patients
por: Niu, Dongling
Publicado: (2021)

Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome
por: Wang, Huidong, et al.
Publicado: (2016)

Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study
por: Johansson, Susanne A., et al.
Publicado: (2017)

Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Wang, He-Yang, et al.
Publicado: (2018)

Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
por: Li, Jianan, et al.
Publicado: (2021)

Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study
por: Yao, Ying, et al.
Publicado: (2019)

Identification of Potential Biological Factors Affecting the Treatment of Ticagrelor After Percutaneous Coronary Intervention in the Chinese Population
por: Yuan, Dongdong, et al.
Publicado: (2022)

Ticagrelor vs. Clopidogrel After Complex Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease
por: Xi, Ziwei, et al.
Publicado: (2021)

Antithrombotic Therapy With Ticagrelor in Atrial Fibrillation Subjects After Percutaneous Coronary Intervention
por: Lu, Wenbin, et al.
Publicado: (2021)

Metabolism of ticagrelor in patients with acute coronary syndromes
por: Adamski, Piotr, et al.
Publicado: (2018)

Comparative Safety and Effectiveness of Ticagrelor versus Clopidogrel in Patients With Acute Coronary Syndrome: An On-Treatment Analysis From a Multicenter Registry
por: Almendro-Delia, Manuel, et al.
Publicado: (2022)

SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
por: Ma, Tingting, et al.
Publicado: (2022)

Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
por: Johnson, Thomas W., et al.
Publicado: (2020)

Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor
por: Birkeland, Kade, et al.
Publicado: (2010)

Critical appraisal of ticagrelor in the management of acute coronary syndrome
por: Nawarskas, James J, et al.
Publicado: (2011)

Comparison of Ticagrelor and Clopidogrel for Patients Undergoing Emergency Percutaneous Coronary Intervention
por: YANG, Bin, et al.
Publicado: (2018)

Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
por: Condello, Francesco, et al.
Publicado: (2021)

Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Liu, Hui-Liang, et al.
Publicado: (2016)

Dyspnoea management in acute coronary syndrome patients treated with ticagrelor
por: Parodi, Guido, et al.
Publicado: (2015)

Clopidogrel versus ticagrelor in the treatment of Chinese patients undergoing percutaneous coronary intervention: effects on platelet function assessed by platelet function tests and mean platelet volume
por: Zhang, Yang, et al.
Publicado: (2021)

Efficacy and safety of ticagrelor monotherapy in patients following percutaneous coronary intervention: A systematic review and meta-analysis
por: Zhang, Wen-bin, et al.
Publicado: (2021)

A Comparative Pharmacodynamic Study of Ticagrelor versus Clopidogrel and Ticagrelor in Patients Undergoing Primary Percutaneous Coronary Intervention: The CAPITAL RELOAD Study
por: Hibbert, Benjamin, et al.
Publicado: (2014)

Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention
por: Marian, Moazez J., et al.
Publicado: (2017)

Perception and self-management of hypertension in Chinese cardiologists (CCHS): a multicenter, large-scale cross-sectional study
por: Hou, Lei, et al.
Publicado: (2019)

Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta‐Analysis
por: Gelbenegger, Georg, et al.
Publicado: (2021)

Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis
por: Wang, Dong, et al.
Publicado: (2018)

Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial
por: Li, Pan, et al.
Publicado: (2016)

Comparison of ticagrelor with clopidogrel on quality of life in patients with acute coronary syndrome
por: Moon, Hyeyeon, et al.
Publicado: (2021)

Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction
por: Scanavini-Filho, Marco Antonio, et al.
Publicado: (2022)

Hospital‐Level Variation in Ticagrelor Use in Patients With Acute Coronary Syndrome
por: Ozaki, Aya F., et al.
Publicado: (2022)

Effect of altitude on ticagrelor-induced dyspnea in patients with acute coronary syndrome
por: Kocabay, Gonenc, et al.
Publicado: (2023)

Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety
por: Dobesh, Paul P, et al.
Publicado: (2014)

Clinical effect of ticagrelor administered in acute coronary syndrome patients following percutaneous coronary intervention
por: LU, YANJIAO, et al.
Publicado: (2016)

Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention
por: Zheng, Wei, et al.
Publicado: (2019)

Combination of Colchicine and Ticagrelor Inhibits Carrageenan-Induced Thrombi in Mice
por: Zhang, BuChun, et al.
Publicado: (2022)

Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers
por: Nie, Shanshan, et al.
Publicado: (2022)

Effect of Ticagrelor on Coronary Blood Flow and Prognosis in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention in Real World
por: Jin, Yan-Yan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_richp2edag6armoeth0ha1ajp0